A single electroporation delivery of a dna vaccine containing the hemagglutinin gene of asian h5n1 avian influenza virus generated a protective antibody response in chickens against a north american virus strain

Clinical and Vaccine Immunology

Volumn 20, Issue 4, 2013, Pages 491-500

  Ogunremi, Oladele ^a   Pasick, John ^b   Kobinger, Gary P ^c   Hannaman, Drew ^d   Berhane, Yohannes ^b   Clavijo, Alfonso ^a,b   Van Drunen Littel Van Den Hurke, Sylvia ^e  

^a CANADIAN FOOD INSPECTION AGENCY   (Canada)

^b CANADIAN FOOD INSPECTION AGENCY   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d Ichor Medical Systems Inc   (United States)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CHICKEN; CONTROLLED STUDY; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HA GENE; HEMAGGLUTINATION INHIBITION; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N2; LOW DRUG DOSE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; SYMPTOM; VIRUS GENE; VIRUS LOAD; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CHICKENS; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; SURVIVAL ANALYSIS; VACCINES, DNA; VIRAL LOAD;

EID: 84876481737     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00577-12     Document Type: Article

References (39)

1. Babiuk S, Baca-Estrada ME, Foldvari M, Storms M, Rabussay D, Widera GL, Babiuk LA. 2002. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 20:3399-3408.
2. Swayne DE. 2006. Principles for vaccine protection in chickens and domestic waterfowl against avian influenza: Emphasis on Asian H5N1 high pathogenicity avian influenza. Ann. N. Y. Acad. Sci. 1081:174-181.
3. Robinson HL, Hunt LA, Webster RG. 1993. Protection against a lethal influenza virus challenge by immunization with a hemagglutininexpressing plasmid DNA. Vaccine 11:957-960.
4. Webster RG, Kawaoka Y, Taylor J, Weinberg R, Paoletti E. 1991. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 9:303-308.
5. Steensels M, Van Borm S, Lambrecht B, De Vriese J, Le Gros FX, Bublot M, van den Berg T. 2007. Efficacy of an inactivated and a fowlpoxvectored vaccine in Muscovy ducks against an Asian H5N1 highly pathogenic avian influenza viral challenge. Avian Dis. 51(1 Suppl):325-331.
6. Webster RG, Webby RJ, Hoffmann E, Rodenberg J, Kumar M, Chu HJ, Seiler P, Krauss S, Songserm T. 2006. The immunogenicity and efficacy against H5N1 challenge of reverse genetics-derived H5N3 influenza vaccine in ducks and chickens. Virology 351:303-311.
7. Tumpey TM, Kapczynski DR, Swayne DE. 2004. Comparative susceptibility of chickens and turkeys to avian influenza A H72N virus infection and protective efficacy of a commercial avian influenza H7N2 virus vaccine. Avian Dis. 48:167-176.
8. Chambers TM, Kawaoka Y, Webster RG. 1988. Protection of chickens from lethal influenza infection by vaccine-expressed hemagglutinin. Virology 167:414-421.
9. Swayne DE, Kapczynski D. 2008. Strategies and challenges of eliciting immunity against avian influenza virus in birds. Immunol. Rev. 225:314-331.
10. Treanor J, Wright PF. 2003. Immune correlates of protection against influenza in the human challenge model. Dev. Biol. (Basel) 115:97-104.
11. Kumar M, Chu HJ, Rodenberg J, Krauss S, Webster RG. 2007. Association of serologic and protective responses of avian influenza vaccines in chickens. Avian Dis. 51(1 Suppl):481-483.
12. Yang M, Clavijo A, Graham J, Salo T, Hole K, Berhane Y. 2009. Production and diagnostic application of monoclonal antibodies against influenza virus H5. J. Virol. Methods 162:194-202.
13. van Drunen Littel-van den Hurk S, Lawman Z, Wilson D, Luxembourg A, Ellefsen B, van den Hurk JV, Hannaman D. 2010. Electroporation enhances immune responses and protection induced by a bovine viral diarrhea DNA vaccine in newborn calves with maternal antibodies. Vaccine 28:6445-6454.
14. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. 1993. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. U. S. A. 90:11478-11482.
15. Suarez DL, Schultz-Cherry S. 2000. The effect of eukaryotic expression vectors and adjuvants on DNA vaccines in chickens using an avian influenza model. Avian Dis. 44:861-868.
16. Bachy M, Boudet F, Bureau M, Girerd-Chambaz Y, Wils P, Scherman D, Meric C. 2001. Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse. Vaccine 19:1688-1693.
17. Selby M, Goldbeck C, Pertile T, Walsh R, Ulmer J. 2000. Enhancement of DNA vaccine potency by electroporation in vivo. J. Biotechnol. 83:147-152.
18. Kutzler MA, Weiner DB. 2008. DNA vaccines: Ready for prime time? Nat. Rev. Genet. 9:776-788.
19. Patel A, Tran K, Gray M, Li Y, Ao Z, Yao X, Kobasa D, Kobinger GP. 2009. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 27:3083-3089.
20. World Organisation for Animal Health. 2011. Avian influenza. Manual of diagnostic tests and vaccines for terrestrial animals. Chapter 2.3.4. http://www .oie.int/fileadmin/Home/eng/Health-standards/tahm/2.03.04-AI.pdf. Accessed 18 March 2012.
21. Reference deleted.
22. Ogunremi O, Benjamin J. 2010. Development and field evaluation of a new serological test for Taenia saginata cysticercosis. Vet. Parasitol. 169: 93-101.
23. Greiner M. 1995. Two-graph receiver operating characteristic (TGROC): A Microsoft-EXCEL template for the selection of cut-off values in diagnostic tests. J. Immunol. Methods 185:145-146.
24. Webster RG, Kawaoka Y, Bean WJ, Beard CW, Brugh M. 1985. Chemotherapy and vaccination: A possible strategy for the control of highly virulent influenza virus. J. Virol. 55:173-176.
25. Spackman E, Senne DA, Myers TJ, Bulaga LL, Garber LP, Perdue ML, Lohman K, Daum LT, Suarez DL. 2002. Development of a real-time reverse transcription PCR assay for type A influenza virus and avian H5 and H7 hemagglutinin subtypes. J. Clin. Microbiol. 40:3256-3260.
26. Kaverin NV, Rudneva IA, Ilyushina NA, Varich NL, Lipatov AS, Smirnov YA, Govorkova EA, Gitelman AK, Lvov DK, Webster RG. 2002. Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J. Gen. Virol. 83:2497-2505.
27. Philpott M, Hioe C, Sheerar M, Hinshaw VS. 1990. Hemagglutinin mutations related to attenuation and altered cell tropism of a virulent avian influenza A virus. J. Virol. 64:2941-2947.
28. Philpott M, Easterday BC, Hinshaw VS. 1989., Neutralizing epitopes of the H5 hemagglutinin from a virulent avian influenza virus and their relationship to pathogenicity. J. Virol. 63:3453-3458.
29. Domenech J, Dauphin G, Rushton J, McGrane J, Lubroth J, Tripodi A, Gilbert J, Sims LD. 2009. Experiences with vaccination in countries endemically infected with highly pathogenic avian influenza: The Food and Agriculture Organization perspective. Rev. Sci. Tech. 28:293-305.
30. Capua I, Cattoli G, Marangon S, Bortolotti L, Ortali G. 2002. Strategies for the control of avian influenza in Italy. Vet. Rec. 150:223.
31. Halvorson DA. 2009. Prevention and management of avian influenza outbreaks: Experiences from the United States of America. Rev. Sci. Tech. 28:359-369.
32. Halvorson DA, Frame DD, Friendshuh AJ, Shaw DP. 1998. Outbreaks of low pathogenicity avian influenza in U.S.A., p 36-46. In Swayne DE, Slemons RD (ed), Proceedings of the Fourth International Symposium of Avian Influenza, the University of Georgia, Athens, GA.
33. McCapes RH, Bankowski RA. 1985. Use of avian influenza vaccines in California turkey breeders-medical rationale, p 31-35. In Easterday BC (ed), Proceedings of the Second International Symposium on Avian Influenza, the University of Georgia, Athens, GA.
34. Price RJ. 1982. Commercial avian influenza vaccines, p 178-179. In Bankowski RA (ed), Proceedings of the First Avian Influenza Symposium, 1981. Carter Composition Corp., Richmond, VA.
35. van Drunen Littel-Van Den Hurk S, Hannaman D. 2010. Electroporation of DNA immunization: Clinical application. Expert Rev. Vaccines 9:503-517.
36. Rush CM, Mitchell TJ, Garside P. 2010. A detailed characterisation of the distribution and presentation of DNA vaccine encoded antigen. Vaccine 28:1620-1634.
37. Provinciali M, Barucca A, Pierpaoli E, Orlando F, Pierpaoli S, Smorlesi A. 2011. In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging. Cancer Immunol. Immunother. 61:363-371.
38. Roos AK, Eriksson F, Timmons JA, Gerhardt J, Nyman U, Gudmundsdotter L, Bråve A, Wahren B, Pisa P. 2009. Skin electroporation: Effects on transgene expression, DNA persistence and local tissue environment. PLoS One 4:e7226. doi:10.1371/journal.pone.0007226.
39. Ogunremi O, Pasick J, Berhane M. Needle-free delivery of an inactivated H5N3 avian influenza vaccine elicits potent antibody responses in chickens. Can. J. Vet. Res., in press.